Regulatory T (T reg ) cells represent an essential component of peripheral tolerance. Given their potently immunosuppressive functions that is orchestrated by the lineage-defining transcription factor forkhead box protein 3 (FoxP3), clinical modulation of these cells in autoimmunity and cancer is a promising therapeutic target. However, recent evidence in mice and humans indicates that T reg cells represent a phenotypically and functionally heterogeneic population. Indeed, both suppressive and non-suppressive T reg cells exist in human blood that are otherwise indistinguishable from one another using classical T reg cell markers such as CD25 and FoxP3. Moreover, murine T reg cells display a degree of plasticity through which they acquire the trafficking pathways needed to home to tissues containing target effector T (T eff ) cells. However, this plasticity can also result in T reg cell lineage instability and acquisition of proinflammatory T eff cell functions. Consequently, these dysfunctional CD4 + FoxP3 + T cells in human and mouse may fail to maintain peripheral tolerance and instead support immunopathology. The mechanisms driving human T reg cell dysfunction are largely undefined, and obscured by the scarcity of reliable immunophenotypical markers and the disregard paid to T reg cell antigen-specificity in functional assays. Here, we review the mechanisms controlling the stability of the FoxP3 + T reg cell lineage phenotype. Particular attention will be paid to the developmental and functional heterogeneity of human T reg cells, and how abrogating these mechanisms can lead to lineage instability and T reg cell dysfunction in diseases like immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome, type 1 diabetes, rheumatoid arthritis and cancer.
Introduction
Regulatory T (T reg ) cells are essential mediators of peripheral tolerance to self and non-self-antigens [1] . T reg cells achieve this immunoregulatory control through multiple suppressive mechanisms that inhibit cells of innate immunity, antigen-presenting cell (APC) functions, as well as adaptive B, CD4 + or CD8 + effector T (T eff ) cell responses [2] . Pioneering experiments identified these potently immunosuppressive cells as CD4 + CD25 + T cells as the transfer of CD25-depleted splenocytes into lymphopenic mice conferred multi-organ autoimmunity [3] . Homologous CD4 + CD25 high human counterparts were identified shortly thereafter [4] [5] [6] [7] [8] . In 2003, forkhead box P3 (FoxP3) was identified as the lineage-defining transcription factor of T reg cells. Indeed, gene deletion or abrogation of its functions caused severe inflammatory autoimmune disorders in mice and humans by abolishing T reg cell development [9] [10] [11] .
FoxP3 + T reg cells can be categorized into two ontogenic categories: thymic-derived/natural T reg (tT reg ) cells and
FoxP3, the master regulator of T reg cell lineage commitment
FoxP3, a 431 amino acid forkhead winged helix family transcriptional regulator, is the master transcription factor driving the genetic programming of T reg cells [17] . Natural or experimental mutations of the foxp3 gene result in congenital deficiencies in T reg cell development and function. These lead to spontaneous, multi-organ, immune pathology in scurfy mice and humans with immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome [9] [10] [11] .
FoxP3 acts primarily as a transcriptional repressor of key genes involved in T cell activation and effector functions, including proliferation and synthesis of proinflammatory cytokines [e.g. IL-2, IL-4, IL-17A and interferon (IFN)-γ], all the while endowing the cell with potent suppressive functions [18, 19] . Sustained expression of FoxP3 in T reg cells is required for lineage commitment and stability, and several key mechanisms including cytokine signaling, epigenetic control of the foxp3 locus and interactions of FoxP3 with other proteins, contribute to the regulation of FoxP3 expression and, consequently, maintenance of peripheral tolerance (Fig. 1 ).
Cytokine control of FoxP3 + T reg cell homeostasis
IL-2 is necessary for global T reg cell homeostasis by promoting their development, survival and function in the thymus and periphery [20] [21] [22] . IL-2 activates the signal transducer and activator of transcription (STAT)-5, which binds to several sites on the foxp3 promoter to enhance FoxP3 expression and thus establish the T reg cell genetic program. A defining feature of T reg cells, unlike other T cell subsets, is their constitutive expression of CD25, the α chain of the heterotrimeric high-affinity IL-2R. Indeed, T reg cells have a higher sensitivity to IL-2 signaling than T eff cells due to preferential binding of IL-2 through high expression of CD25 and higher activity of PP1 and PP2A phosphatases which modulate IL-2 signaling [23] . Defects in IL-2 signaling (e.g. mutations in CD25) can give rise to IPEX-like autoimmunity as a consequence of T reg cell dysfunction [24] .
TGF-β is another essential cytokine promoting the development of T reg cells. In conjunction with TCR stimulation, TGF-β mediates the conversion of CD4 + FoxP3 − naïve T conv cells into iT reg /pT reg cells (in-vitro/in-vivo) [25] . TGF-β signaling activates Smad2/3 transcription factors, which bind directly to enhancer regions of the foxp3 locus to promote FoxP3 expression in these pT reg cells [25, 26] . TGF-β signaling is also critical for tT reg cell development and function. Although a CD4 + T cell-specific deletion of the TGF-β receptor II (TGF-βRII) in mice had no defect in T reg cell frequencies, mice nevertheless developed multi-organ T cell-mediated autoimmunity, suggesting a defect in immunoregulation [27, 28] . Moreover, a specific knock-out of the TGF-β receptor I (TGF-βRI) in murine T cells curtailed tT reg cell generation within the first week of life of neonatal mice, supporting a requirement for TGF-β in tT reg cell development [29] . Additionally, intrathymic injection of precursor CD4 − CD8 − thymocytes from cd4 Cre tgfbr1 fl/fl mice into syngeneic wild-type hosts failed to yield tT reg cells [30] . Thus, global T reg cell development is dependent on TGF-β signalling.
Epigenetic regulation of FoxP3 expression
Enzymatic demethylation of specific cytosine-phosphateguanine (CpG) motifs within the intronic enhancer evolutionary conserved non-coding sequence (CNS) 2, also called the T reg -specific demethylated region (TSDR), is another critical mechanism maintaining FoxP3 expression in T reg cells and is a feature that is absent in T conv cells [31] [32] [33] . Demethylation of these critical non-coding sequences opens up the foxp3 enhancer region to large multi-molecular complexes containing FoxP3, c-Rel, nuclear factor of activated T cells (NFAT), STAT-5, runtrelated transcription factor 1-core-binding factor (Runx1-CBF)β, cAMP responsive element-binding/activating transcription factor (Creb/ATF) and ETS proto-oncogene 1 (Ets1). These multi-molecular complexes bring the CNS2 into contact with the foxp3 promoter, thereby driving FoxP3 expression. Indeed, it was recently demonstrated that demethylation of the CNS2 resulted in enhanced T reg cell lineage stability by increasing T reg cell sensitivity to IL-2 through greater STAT-5 occupancy of the foxp3 enhancer [34] . Accordingly, recruitment of the DNA methylase Dnmt1 to the foxp3 promoter and its subsequent methylation severely impaired the maintenance of FoxP3. Demethylation of CNS2 in T reg cells is mediated by the 10-11 translocation (Tet) family of demethylases, which are themselves recruited to the foxp3 locus by STAT-5 [35] . Deletion of Tet1 and Tet2 in murine T reg cells yields severe autoimmunity as a consequence of poor T reg cell lineage commitment.
CNS1 is also important for T reg cell lineage commitment. Deletion of CNS1, which contains a binding site for Smad2/3 upstream of CNS2, abrogates pT reg cell development in mice and leads to inflammation at mucosal sites [36] . Moreover, the newly identified CNS0 was also shown to be necessary for T reg cell stability [37] . CNS0 is bound by the genomic organizer Satb1 in FoxP3 − tT reg cell thymic precursors and alters chromatin accessibility in order to orchestrate the Fig. 1 . Mechanisms preserving the stability of the regulatory T cell (T reg ) phenotype. T reg cell lineage stability is reliant on the strength of forkhead box protein 3 (FoxP3) expression. There are several mechanisms in place to ensure robust FoxP3 expression in T reg cells. A, T cell receptor (TCR) signaling leads to nuclear factor of activated T cells (NFAT) binding to the CNS2 region of the foxp3 locus for transactivation of gene expression. B, Constitutive High level of CD25 expression, the interleukin (IL)-2 receptor α, on the T reg cell surface confers a high sensitivity to IL-2 in the environment. IL-2 signaling through Janus kinase (Jak)1 and Jak3 result in signal transducer and activator of transcription (STAT-5) phosphorylation and dimerization and subsequent translocation into the nucleus. Phosphorylated (p)STAT-5 binding to the conserved non-coding DNA sequence (CNS)2 drives FoxP3 expression. C, Transforming growth factor (TGF)-β signaling through TGF-βRI and TGF-βRII result in Smad2/3 phosphorylation, association with the transcription Smad4 and the translocation of the complex into the nucleus. Smad2/3/4 bind to the foxp3 promoter and drive FoxP3 expression. In the presence of TCR signaling, TGF-β-driven FoxP3 expression in naïve CD4 + conventional T (T conv ) results in induced (i)T reg /peripheral (p)T reg induction. D, To enable transcription factor binding to the foxp3 locus enhancer region, certain sites are specifically demethylated in T reg cells. In the CNS2 enhancer region, this is referred to as the T reg -specific demethylated region (TSDR). Demethylation of the TSDR is mediated by the 10-11 translocation (Tet) family demethylases Tet1 and Tet2. DNA methyl transferases (Dnmt) such as Dnmt1 methylate the TSDR and destabilize Foxp3 expression. E, Once FoxP3 is expressed, it heterodimerizes and can associate with many different binding partners (~700), including transcription factors, histone deacetylases and histone acetyl transferases. Binding to these proteins are necessary for transcriptional repression of various genes (il7ra, ifng, il2) and activation of others (il2ra, ctla4, foxp3). F, Significant focus has been devoted to studying the environmental signals controlling FoxP3 expression. Phosphoinositide-3-kinase-protein kinase B (PI3K-Akt) signaling downstream TCR and CD28 signaling is needed for transient mammalian target of rapamycin complex 1 (mTORC1) activation and consolidation of the T reg cell phenotype. However, chronic activation of mTORC1 (e.g. through environmental signals such as glutamine) result in sustained mTORC1 activation and therefore deregulation of T reg cells. Thus, mTORC1 inhibitors (e.g. rapamycin) are used in the in-vitro expansion of T reg cells. changes needed for future FoxP3 expression and T reg cell development in mice.
FoxP3 binding-partners and T reg cell stability
FoxP3 imparts its functions by directly or indirectly binding to ~ 700 transcriptional promoters, either repressing or activating the target genes [38, 39] . However, the transcriptional control of most genes inherent to the T reg cell transcriptional program is achieved by the indirect binding of FoxP3 through other molecular factors. For example, complexes between FoxP3 and NFAT, nuclear factor (NF)-κB, acute myeloid leukemia 1 (AML1)/Runx1, activator protein 1 (AP1) and retinoic acid orphan receptor (ROR)α transcription factors are known to impair the NFAT/AP1 transcriptional program that leads to il2 expression in T conv cells, thereby maintaining anergy in T reg cells [1] . To identify other FoxP3 binding partners, Rudra et al. expressed the prokaryotic biotin ligase, BirA, and FoxP3 with an N-terminal BirA ligase biotinylation site in a murine T cell hybridoma line to purify protein complexes containing FoxP3 and identified 361 binding partners by mass spectrometry [40] . Along with FoxP3, these binding partners formed a complex transcriptional program with multiple positive and negative feedback loops consolidating the T reg cell transcriptional program. Hence, FoxP3 is necessary but not sufficient for maintaining the T reg cell phenotype [40, 41] .
Key binding partners of FoxP3 include several histone deacetylases (HDAC) such as HDAC1, 7 and 9, and histone acetyltransferases (HAT), such as the Tatinteracting protein 60 (TIP60) and p300 [42] [43] [44] . Interactions with these proteins are necessary for transcriptional silencing of target genes as well as for protein modifications that enhance FoxP3 function. For example, acetylation of FoxP3 upon complexing with p300 allows it to evade proteasomal degradation, which constitutes a post-translational mechanism of FoxP3 stability [43] . Furthermore, we have recently shown that abrogating the FoxP3-Tat-interacting protein 60 (TIP60) interaction, a defect caused by the germline foxp3 A384T IPEX mutation, relieves human T reg cell suppressive capacity while retaining major aspects of the T reg cell phenotype including the repression of proliferation and inflammatory cytokines [45] . Restoring this interaction using a TIP60 allosteric modifier rescued FoxP3 functions and T reg cell suppressive capacity in vitro and in vivo. Thus, several mechanisms maintain FoxP3 stability and consequently establish the requisite transcriptional program to ensure FoxP3 + T reg cell functional development.
Functional heterogeneity among human FoxP3 + T reg cells
Despite FoxP3 ensuring a robust immunosuppressive phenotype, significant functional heterogeneity exists among human FoxP3 + T reg cells. We previously developed a single-cell strategy to examine the phenotypical and functional heterogeneity of human CD4 + CD25 high CD127 low T reg cells relative to FoxP3 expression from blood of healthy individuals [16] . CD4 + CD25 high/bright T reg cells, albeit highly enriched in suppressive FoxP3 + T cells, harbour a pool of bona fide FoxP3 + T reg cells with compromised suppressive function, despite the maintenance of hallmark phenotypic, epigenetic and transcriptional features of T reg cells. These FoxP3 + T reg cells with compromised suppressive function also produce proinflammatory cytokines such as IL-2, IL-17 and IFN-γ following polyclonal activation [16] . Whether this heterogeneity relates to FoxP3 + T reg cell subsets that have acquired unique effector functions or T reg cells losing their phenotype remains to be determined. These non-suppressive CD25 high FoxP3 + cells in healthy peripheral blood may be involved in the onset of autoimmune or inflammatory states, and further characterization is needed to understand more clearly their roles in health and disease.
We recently identified Helios, an Ikaros family transcription factor, to be preferentially expressed on suppressive T reg cells as opposed to non-suppressive T reg cells in human blood during immune quiescence and in disease [46] . Although, Helios was initially proposed as a marker for differentiating between tT reg and iT reg cells, there are no data supporting this definition in humans. We further demonstrated that co-expression of the surface receptors T cell immunoreceptor with immunoglobulin (Ig) and ITIM domains (TIGIT) and Fc receptor-like 3 (FcRL3) identified most Helios + T reg cells in the periphery and were absent from T eff cells at the steady state and following TCR stimulation [46] .
Antigen-specific T reg cell functions
Heterogeneity in T reg cell function also lies in TCR specificities that drive their developmental ontogeny, peripheral homeostasis and effector functions. As stated earlier, tT reg and pT reg cells differ in their ontogenies. Consequently, tT reg cells possess a diverse, self-restricted TCR repertoire distinct from T conv cells, whereas pT reg cells retain the antigen specificities of their naïve T conv precursors. In-vitro evidence shows that tT reg cell suppressive function is TCR activation-dependent, and although antigen non-specific suppression has been described, antigen-specific signals are largely viewed as necessary for optimal tT reg cell suppressive functions within the periphery [47] [48] [49] . For example, pancreatic autoantigen-specific T reg cells and myelin basic protein (MBP)-specific T reg cells preferentially prevent disease in mouse models of type-1 diabetes (T1D) and multiple sclerosis, respectively [50] [51] [52] . Nevertheless, naïve (CD25 low CD45RA + ) non-antigen-experienced tT reg cell populations are critical for homeostasis of the global tT reg cell pool [53] . Expressing high levels of the prosurvival molecule Bcl-2 and relying on IL-7 signaling in the periphery, naïve tT reg cells are rapidly proliferative and readily differentiate into potently suppressive memory tT reg cells upon TCR engagement by their cognate self-antigen [53, 54] .
Allergy represents the best-studied area regarding the functional consequences of pT reg cell antigen specificity. Barrier tissues are constantly exposed to a myriad of environmental, dietary and commensal microbial antigens requiring homeostatic immune control mediated by the local T reg or T eff cell antigen-specific repertoires. Consequently, they are particularly specialized sites for the de-novo generation of pT reg cells in order to ensure immune homeostasis and maintain tolerance [55, 56] . A break of T reg cell-mediated tolerance often results in allergic inflammation at these sites. Specialized APCs, such as alveolar macrophages in the lungs and CD103 + dendritic cells (DCs) in the intestinal mucosa, favour pT reg cell differentiation via a TGF-β-or retinoic aciddependent process [57] [58] [59] . In the lungs, the TCR specificities from pT reg cells are often restricted to common aeroantigens (e.g. house dust mite, plant pollen, birch and Aspergillus fumigatus), and dampen allergic inflammation [60] . Bacher et al. recently developed an antigenreactive T cell enrichment technology to study aeroantigen-specific T reg cell function in adults [60] . The technique relied on the detection and isolation from peripheral blood mononuclear cells (PBMC) of rare antigen-specific T reg and T eff cells by the use of 4-1BB (CD137) or CD40L (CD154) expression, respectively [60] . The authors showed that T reg cells specific to common aeroantigens were enriched in allergic adults and existed at greater numbers than aeroantigen-specific T eff cells, thus leading to the hypothesis that aeroantigenspecific T reg cells suppressed T eff cell expansion. In other barrier tissues such as the gut, pT reg cells maintain tolerance towards the diversity of commensal microorganisms and food antigens to which the immune system is continuously being exposed [55, 56] .
Antigen-specific T reg cells have also been implicated to play a role in autoimmunity and cancer. Ooi et al. recently demonstrated that T reg cells with a TCR selfrestriction towards the type IV collagen α chain (peptides 135-145) presented specifically on human leukocyte antigen D-related (HLA-DR1) provided dominant resistance to Goodpasture's syndrome, a rapidly progressive and fatal autoimmune disease of the kidneys and lungs, in humanized mice [48] . In rheumatoid arthritis (RA), TCR-sequencing of synovial CD14 − CD4 + CD25 high CD127 − T reg cells yielded a few expanded clonotypes [61] . These T reg cells were enriched in suppressive and activated (HLA-DR + ) T reg cell subsets, thereby demonstrating a functional relevance for T reg cell antigen-specificity in RA. In cancer, T reg cells play a key role in promoting immune-evasion by cancer cells. For example, increased frequencies of T reg cells specific to NY-ESO-1, an immunogenic tumor antigen, are observed in peripheral blood of melanoma patients [62] , and their frequency correlates with metastatic potential and poor prognosis.
Functional plasticity, or instability, of T reg cells
We and others have shown that adoptive transfer of FoxP3 + T reg cells into lymphopenic mice resulted in a loss of FoxP3 expression, loss of suppressive activity and consequential acquisition of inflammatory characteristics [15] . Experiments conducted in foxp3 GFPCre Rosa26-loxP-stop-loxP-YFP fate mapping mice showed that a significant proportion of T reg cells that expressed FoxP3 at one point in time (YFP + ) lost FoxP3 expression (GFP − ) in homeostatic settings [15] . These YFP + GFP − cells, termed exFoxP3, were phenotypically similar to memory T eff cells and produced proinflammatory cytokines. It is unclear whether exT reg cells originate from bona fide committed tT reg cells, from an uncommitted CD25 low subset found therein, or if they represent T eff cells that have not completely converted into FoxP3 + pT reg cells [63] . Whether T reg cell plasticity occurs in the normal pathophysiology of human disease is currently unknown.
Extrinsic factors promoting the instability of T reg cell function
Cytokine signaling, repeated antigen exposure and methylation patterns within the foxp3 promoter are key factors enabling the stability of T reg cell function. IL-6 is a proinflammatory cytokine known to counteract IL-2 signaling through STAT-3 dimers which occupy STAT-5-binding sites of the foxp3 locus, thereby attenuating FoxP3 expression [22] . Moreover, IL-6 in the presence of TGF-β can favour the development of Th17 cells over pT reg from naïve CD4 + T cells in mice and humans [64] . Whether T reg cells can themselves convert into Th17 cells, thereby demonstrating true plasticity, remains unknown in both humans and mice. The nature and strength of antigenic stimulation also influences T reg stability. Development of tT reg cells in the mouse thymus depends on strong TCR stimulation leading to demethylation of the TSDR and subsequent binding of STAT-5 to the foxp3 locus [65] . In contrast, induction of murine pT reg cells is improved when TCR stimulation is weaker and co-stimulation is reduced [66] . In humans, repeated TCR stimulation of CD4 + CD25 high CD127 low T reg cells attenuated, and even completely abrogated, FoxP3 expression while increasing production of proinflammatory cytokines [67] , although the exFoxP3 cells identified here may have originated from contaminating T eff cells (see Conclusion).
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Functional adaptation of T reg cells
Local inflammatory signals can drive CD4 + T cells to undergo functional plasticity to acquire specialized effector functions in inflammatory sites. Growing evidence indicates that FoxP3 + T reg cells can also acquire tissuespecific adaptations that promote their homing to inflammatory sites for the control of immune responses driven by various T eff cell lineages. T reg cells achieve this by up-regulating the transcription factors of other T cell lineages in the presence of specific polarizing conditions, namely T-bet (Th1), interferon regulator factor 4 (IRF4) and GATA binding protein 3 (GATA3) (Th2) and STAT-3 and RORγt (Th17) [68] [69] [70] [71] . For example, expression of CCR6 (CD196), a chemokine receptor characteristic of Th17 cells, driven by STAT-3 expression in T reg cells, is thought to dampen Th17 cell-mediated inflammation and tissue pathology in crescentic glomerulonephritis, a potent inflammatory kidney disease [72] . However, the co-expression of secondary transcription factors may also represent a transition where T reg cells convert into T eff cells as the acquired transcription factors may endow T reg cells with the ability to produce proinflammatory cytokines. Indeed, human and mouse RORγt + T reg cells obtained through in-vitro Th17 polarizing conditions produce IL-17A and demonstrate attenuated suppressive capacities despite intact FoxP3 expression [71, 73] . Whether these cells can completely convert into FoxP3 − T eff cells or whether this plasticity is reversible remains to be determined. Moreover, whether this occurs in-vivo in humans is completely unknown.
T reg cell dysfunction in human disease
How T reg cell dysfunction occurs and impacts the outcome of human disease is an important question. Here, we will highlight a few key mechanisms leading to T reg cell dysfunction in human disease: (i) genetic defects, (ii) abrogation of T reg cell-promoting signals, (iii) presence of T reg cell destabilizing factors and (iv) co-opting T reg cell suppressive function.
Congenital T reg cell defects: IPEX syndrome, the human 'FoxP3 knock-out'
The most extreme example of T reg cell dysregulation occurs in IPEX syndrome, a sex-linked congenital disease that is frequently fatal within infancy. It is largely caused by single loss-of-function germline point mutations in the Foxp3 locus that abrogate T reg cell function to different degrees [9] . More than 60 such mutations have been identified with a clinical spectrum whose severity is dependent on the nature of the mutation and the protein domain affected [74] . Mutations in the N-terminal proline-rich repressor (PRR) domain often result in improper T reg cell suppressive function and production of proinflammatory cytokines (e.g. E70H and T108M) [75] . Moreover, IPEX mutations on the leucine zipper domain (e.g. ∆E251) prevent FoxP3 from exerting transcriptional control of target genes and are often associated with severe clinical manifestations of autoimmunity. However, most IPEX cases are caused by mutations in the forkhead (FKH) domain of FoxP3, which either prevent DNA-binding (e.g. R397W and I363V) or interactions with other proteins that aid in orchestrating the T reg transcriptional program (e.g. A384T) [45, 75] . Importantly, the presence of a mutation does not necessarily imply diminished FoxP3 protein expression levels (e.g. F373A [76] ), T reg numbers (e.g. A384T [45] ) or even loss of T reg suppressive functions (e.g. R347H). Clearly, the IPEX case demonstrates that, simple enumeration of T reg cells is often not sufficient to make claims about T reg cell function in vivo.
Developmental and homeostatic T reg cell dysfunction in autoimmunity
The IL-2/IL-2R pathway is necessary for the thymic development and peripheral homeostasis of T reg cells, and congenital or homeostatic disruption of key components of this pathway can provoke T reg dysregulation and give rise to a spectrum of diseases ranging from IPEX-like autoimmunity [24] to type 1 diabetes (T1D).
Implications for T1D pathogenesis.
Mouse studies show that a hallmark of diabetes onset is the apoptosis of pancreatic islet T reg cells, alongside decreased CD25 and Bcl-2 expression, suggesting local IL-2 deprivation [77] . In some T1D cohorts, patients have decreased IL-2 production [78] , and diminished CD25 expression within FoxP3 + T reg cells [79] . Long et al. found that IL-2 sensitivity of CD4 + CD25 + T reg cells was decreased in diabetic patients compared to healthy controls [80] . However, this observation was not seen by other studies [23] , or only reproduced when looking at subjects bearing T1D-predisposing mutations on genes of the IL-2 pathway (IL2RA and PTPN2) [81, 82] . Indeed, the IL2RA susceptibility haplotype was associated with decreased sensitivity to low doses of IL-2 in vitro, diminished suppressive function, lower CD25 expression and lower levels of FoxP3 expression by Helios + T reg cells under limiting conditions of IL-2 ( Fig. 2A) [81] . There is still no consensus on whether T reg cell frequencies correlate with T1D onset [81, 83] . Furthermore, some have argued that T eff cells from diabetic subjects are resistant to suppression by T reg cells [84] , possibly through a STAT-3-dependent mechanism [85] .
In-vitro, as stated earlier, diminished FoxP3 expression is correlated with loss of a suppressive phenotype and secretion of proinflammatory cytokines [67] . Indeed, patients with either new-onset [86] or established diabetes [87] have an increased frequency of proinflammatory, cytokine-secreting, less suppressive T reg cells in their peripheral blood. However, it is as yet unknown if this dysfunction is linked causally to poor IL-2 signaling or if it is a consequence of islet inflammation. Altogether, these results indicate that susceptibility mutations in genes of the IL-2 pathway impair T reg cell sensitivity to IL-2 signals, leading to diminished pSTAT-5 levels and reduced expression levels of FoxP3. This dysregulation could ultimately lead to defective suppression by T reg cells.
Translational relevance for immunotherapy. Defects in IL-2 signaling preferentially tamper with T reg cell homeostasis. Therefore, Low-dose IL-2 therapy could specifically stimulate the T reg compartment and re-establish immune homeostasis in diseases such as T1D, graft-versushost disease (GVHD) [88] and hepatitis C virus (HCV)-induced vasculitis [89] . The DF-IL-2 trial showed low-dose aldesleukin [recombinant human (rh)IL-2] increased T reg cell frequency in a dose-dependent manner [90] . In the DILT1D trial, a single dose of aldesleukin improved T reg suppressive function in vitro [91] . In Alopecia areata, an autoimmune disease targeting hair follicles, hair regrowth upon treatment with rhIL-2 was associated with the recruitment of CD4 + CD25 + FoxP3 + cells at the site of lesion and persisted for 2 months after the end of treatment, suggesting that T reg cells require a threshold of IL-2R activation to acquire migratory capacity [92] .
Finding a therapeutic window that allows for specific activation of T reg cells over other immune cell subsets will be key to the successful development of low-dose IL-2 therapy. As harmful cell types such as NK cells, CD4 + and CD8 + T eff cells constitutively express the intermediate-affinity IL-2R, the potential for accelerating the course of the disease exists. Indeed, Todd et al reported that for all doses tested at day 1 post-administration, the plasma concentrations of aldesleukin was higher than the activation threshold of NK cells and activated memory T eff cells [91] . To circumvent these issues, one approach is the engineering of IL-2 superagonists to improve durability and selectivity through increased affinity, prolonged half-life and lower doses. One example is IL-2/CD25 fusion proteins, where IL-2 is bound to CD25 by a non-cleavable linker to increase the persistence of IL-2 and reduce binding to the intermediate-affinity IL-2R [93] . Another investigated compound is IL-2-anti-IL-2 monoclonal antibody immune complexes (IL-2IC) [94] [95] [96] , where IL-2 is bound to the IL-2IC antibody such that the CD25-binding epitope is exposed and the CD122 (IL-2Rβ)-binding epitope is blocked (e.g. clone JES6-1), preferentially inducing the expansion of T reg cells over T conv cells. Moreover, a human IL-2-anti-IL-2 monoclonal antibody (F5111.2) immune complex was generated to preferentially enhance human T reg cell proliferation in humanized mice, and successfully used to ameliorate autoimmunity and GVHD in nonobese diabetic (NOD) mice [97] . Finally, Sockolosky et al. devised a strategy to selectively stimulate engineered T cells in the context of T cell therapy. The infused T cells express a mutant ortho-IL-2Rβ receptor that signals through the native STAT-5 pathway but does not bind to wild-type IL-2. Instead, these receptors bind ortho-IL-2, an engineered cytokine-receptor complex that acts as an agonist of ortho-IL-2Rβ but not of any form of the wildtype IL-2R [98] . They applied this strategy for the expansion of tumor-reactive CD8 + cytotoxic T lymphocytes (CTL) in a mouse model of melanoma. However, a similar approach could be conceived to expand engineered ortho-IL-2Rβ T reg cells and enhance the efficacy of T reg cell therapy.
Inflammation-mediated destabilization of T reg cell function
Proinflammatory cytokines such as IL-6 and TNF-α can interfere with the stability of FoxP3 expression in T reg cells, alter the T reg /T eff balance locally or systemically and ultimately provoke a loss of peripheral tolerance. Indeed, IL-6 and TNF-α are readily over-expressed in a number of autoimmune and chronic inflammatory conditions and prompts us to consider its relevance as a target of immunotherapy in autoimmunity.
The case for rheumatoid arthritis (RA). The inflammatory environment of the synovial pannus in RA represents an obvious setting where cytokine-mediated T reg cell dysfunction may occur. High levels of IL-6 may inhibit T reg cell homeostasis and function and enhance the development of proinflammatory T cell subsets. One evidence in support of IL-6-mediated dysfunction of T reg cells is the preferential development of Th17 cells over T reg cells in the periphery of RA patients [99, 100] . This reciprocal regulation can be explained as, in the presence of TGF-β, IL-6 enhances the expression of RORγt through STAT-3 while repressing FoxP3 expression (Fig. 2B) .
Another proinflammatory cytokine affecting T reg cell function is TNF-α, which signals via the TNF-RII receptor, and can subsequently down-regulate FoxP3 expression and alter T reg cell suppressive function [101] . TNF-α may also impair T reg cell function by altering the formation of the immunological synapse between APCs and T reg cells. Here, PKCθ plays a role in the integration of TCR and CD28 signals in T eff cells upstream of NF-κB. Contrary to T conv cells, PKCθ is sequestered from the immunological synapse in T reg cells. TNF-α promotes the recruitment of PKCθ to the TCR in T reg cells, and through downstream Akt signalling inhibits their suppressive capacity (Fig. 2B) . Consistently, in-vitro administration of a PKCθ inhibitor on T reg cells from RA patients enhanced their suppressive function [102] .
However, studies evaluating the function of T reg cells in RA reveal inconsistent findings. While in new-onset patients or during disease flares the frequency of T reg cells in circulation is diminished [103] , T reg cell frequencies are normal in patients with clinically managed disease. However, a defect in repression, and not in suppressive function, of proinflammatory cytokines was reported in T reg cells in RA [104] , linked to defective CTLA-4 expression [105] . Furthermore, Van Amelsfort et al. reported that synovial T reg cells from RA patients have a very activated phenotype and that synovial T eff cells are resistant to suppression [106] . Indeed, in addition to dysregulating T reg cells, IL-6 and TNF-α signaling render T eff cells resistant to suppression via a protein kinase B (PKB)-dependent mechanism [107] .
Translational relevance for immunotherapy. IL-6 and TNF also contribute to systemic symptoms such as fever and asthenia, and fuel tissue damage through recruitment of neutrophils to the inflamed joints and the differentiation REVIEW SERIES: REGULATORY T CELLS of osteoclasts through the NF-κB pathway. Consequently, antibodies directed against these cytokines were developed to block their signaling. Anti-TNF pharmacological agents such as etanercept, adalimumab and infliximab are a major part of the therapeutic arsenal available to treat RA. Anti-TNF treatment induces an increase in circulating T reg cells in responding patients, which correlates with a decrease in the titres of C-reactive protein, a biomarker of inflammation [108] . Tocilizumab, an IL-6R inhibitor, has been authorized as a second line of treatment for RA patients, after failure of methotrexate or anti-TNFs. As observed with anti-TNF drugs, the clinical benefits of tocilizumab treatment are accompanied by an increase in the frequency of peripheral T reg cells after 6 months of treatment [101] .
Co-opting T reg cell suppressive function in cancer
Cancer immunity provides a setting where increased T reg cell suppression contributes to cancer onset, progression and metastasis. To sustain their growth and gain the potential to metastasize, tumors develop a variety of tumorinduced immunosuppressive mechanisms to escape antitumor immunity, such as the expression or secretion of anti-inflammatory mediators [indoleamine 2,3-dioxygenase (IDO), IL-10, TGF-β], and the recruitment of a wide variety of suppressive leukocytes such as T reg cells, myeloidderived suppressor cells (MDSCs), tolerogenic DCs and tumor-associated macrophages (TAMs).
Establishment of a T reg cell niche in the tumor microenvironment. Tumor cells contribute to the establishment of a T reg cell niche by expressing IDO, an enzyme involved in tryptophan degradation. Its expression diminishes tryptophan availability and produces metabolites that induce T cell apoptosis [109] while promoting increased T reg cell frequencies in the tumor infiltrate (Fig. 3) . Reprogramming of T reg cells into Th17 cells has been shown to promote early anti-tumor CTL responses [110] . However, IDO inhibits this process by suppressing IL-6 secretion in DCs and through the GCN2 kinase pathway in FoxP3 + cells. Finally, IDO expression also silences the mTORC2/Akt pathway, thus stabilizing the T reg cell lineage inside the tumor microenvironment [111] .
T reg cells play an essential role in establishing immunosuppression in the tumor microenvironment. Indeed, depletion of T reg cells with an anti-CD25 monoclonal antibody (mAb) leads to tumor clearance in murine syngeneic tumor models [112] . T reg cells infiltrate several types of human cancers, including melanoma, breast, pancreas and liver [113] . Higher frequencies of tumorinfiltrating T reg cells have been correlated with worse prognosis and metastatic potential. In the example of ovarian cancer, a high frequency of infiltrating T reg cells and a decreased CTL to T reg cell ratio have both been associated with reduced survival of patients [114, 115] , consistent with T reg cells suppressing anti-tumoral immune response. Tumor-infiltrating T reg cells also display a very activated phenotype and have high levels of expression of immune checkpoint molecules such as CTLA-4 (CD152), programmed cell death 1 (PD-1) (CD279) [116] and TIGIT [117] , and activation markers such as GITR [118] . These data point towards enhanced activity of T reg cells in the tumor microenvironment contributing to immune evasion.
Translational relevance for immunotherapy. Immune check point inhibitors were developed following the rationale that these biologics compete with the binding of natural ligands to the target co-inhibitory receptor, thus alleviating T conv and CTL inhibitory signaling. Numerous molecules targeting these pathways have been developed successfully for the treatment of many cancers, such as anti-CTLA-4 mAbs (ipilimumab, tremelimumab) and anti-PD-1 mAbs (nivolumab, pembrolizumab).
Studies now show that the protective effect of some of these biologics was through impairment of T reg cell function. Since it is abolished in FcγR -/-mice, the protective effect of anti-CTLA-4 is very likely mediated by antibody-dependent cell-mediated cytotoxicity (ADCC) [119] . Indeed, depletion of T reg cells in a mouse model of melanoma was dependent on the presence of FcγR-expressing macrophages infiltrating the tumor [120] . In melanoma patients, ADCC assays showed depletion of T reg cells through the interaction of ipilimumab and FcγRIIIA + monocytes. Furthermore, responders to ipilimumab treatment have increased proportions of macrophages in their tumors [121] , and treatment efficacy is correlated with decreasing frequencies of T reg cells in tumors [122] . In contrast, tremelimumab, another anti-CTLA-4 mAb, likely functions without ADCC of T reg cells as it suppresses T reg cell function without affecting cell numbers [123] . Therefore, research is needed to assess the impact of check point inhibitors on the functional dynamics of T reg cell subsets in blood and in particular within the tumor microenvironment.
For example, the role of CTLA-4 in T reg cell suppressive function is well established. CTLA-4 acts in a cellintrinsic manner by competing with CD28 for its shared ligands. It also acts on APCs by inducing IDO expression [124] and reducing surface expression of CD80 and CD86 through endocytosis and down-regulating transcription of their mRNA [125] . This leads to the emergence of tolerogenic DCs and limits the availability of co-stimulatory ligands to T eff cells.
Conversely, PD-1 is also highly expressed on T reg cells, but its role is not well identified. In melanoma patients, in-vitro treatment with nivolumab down-regulated FoxP3 expression in sorted T reg cells [126] and inhibited T reg cell suppressive function [127] . However, PD-1 -/-mice have a similar frequency of circulating T reg cells to their wild-type counterparts, and do not display a diminished suppressive capacity [128] . Nevertheless, PD-1 -/-CD4 + T cells have a diminished capacity to differentiate into pT reg cells when transferred into lymphopenic hosts [128] . Indeed, the PD-L1/ PD-1 pathway plays a role in the development of pT reg cells by synergizing with TGF-β signaling through Smad3 to promote the conversion of naïve T cells into iT reg cells. Furthermore, PD-1 signaling inhibits the PI3K/Akt pathway, which is known to destabilize FoxP3 expression [129] . Taken together, these results suggest that PD-1 does not necessarily play a role in T reg cell suppressive function but regulates their homeostasis and stability, thus contributing to the regulation of the T reg /T eff cell balance.
Conclusion and future perspectives
Despite the enormous efforts by the immunological community to characterize the molecular and cellular basis of T reg cell development and function in health and disease, several knowledge gaps remain in this area 
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which future research must address. Various mechanisms ensure a robust and sustained immunosuppressive phenotype in T reg cells. However, there is significant functional and phenotypical heterogeneity that remains to be captured in human disease. One of the future priorities relate to the urgent need for novel strategies to monitor T reg cell function in human blood more effectively, and in particular in tissues, in states of health and disease. Part of the problem lies with the phenotypical markers used to distinguish human T reg cells and subsets found therein from a variety of T conv cells. Both CD25 and FoxP3, the quintessential markers of T reg cells, are up-regulated on T conv cells upon TCR stimulation, and can only be used in situations of immune quiescence, not states of immune activation or inflammation. Other markers have been proposed to overcome this issue. For example, T reg cells are often defined as CD127 low given the inverse correlation between CD127 and FoxP3 expression [130, 131] . Nevertheless, this gating strategy fails to eliminate activated T eff cells and excludes a large proportion of bona fide T reg cells. More recently described T reg cell markers include HLA-DR, CTLA-4, CCR6, GARP, CD15s, CD39, CD49d, CD147, TNFRII, GITR and LAP (Table 1) [132] . Nonetheless, these markers are readily modulated on the surface of T reg and T conv cells consequently impeding proper discrimination and their use for downstream functional and phenotypical studies. We recently demonstrated that TIGIT and FcRL3 are reliable and specific markers for identifying and sorting Helios + T reg cells, and given the stable suppressive phenotype of these cells, we envision that sorted TIGIT + FcRL3 + CD25 high CD127 low cells can be isolated and clinically manipulated for therapeutic use [46] .
Another issue that has thus far prevented a proper definition of T reg cell function in human disease is the lack of discrimination of antigen-specific responses, particularly in conventional, in-vitro polyclonal suppression assays. These methods mask the important effects of antigen-specific T reg cells that may serve different physiological roles than other T reg cell subsets (e.g. aeroantigenspecific T reg cells maintaining tolerance to airborne allergens, but not necessarily counteracting inflammation following pulmonary viral infections). Novel methodologies are emerging now to understand more clearly the antigen-specific effects of T reg cells in human disease. MHC-II tetramer technology, which has largely been ineffective at reliably isolating rare CD4 + TCR specificities, is being vastly improved through adjustments such as barcoding to improve the number of epitopes studied, or dual staining of identically loaded tetramers with different fluorochromes, in conjunction with surface markers such as CD137 to improve specificity and isolate antigenstimulated T reg cells by flow cytometry. Ultimately, these important advancements will enable us to monitor T reg cell functions in unprecedented depth, thereby enhancing our understanding of T reg cells in human health and disease.
Finally, several hurdles affect the therapeutic potential of T reg cells in disease. Novel strategies will need to be developed to overcome the limitations related to survival and cell persistence in vivo, stability of the T reg cell functional phenotype and selective engagement or repression of antigen-specific responses in defined disease settings. In this regard, a better understanding of the genetic factors [single nucleotide polymorphisms (SNPs) or epigenetic], mechanisms of transcriptional regulation (splice isoforms, miRNAs and transcription factor activity) and post-translational modifications (phosphorylation, acetylation or ubiquitination) influencing FoxP3 gene and protein expression or activity will be required to further modulate the function of endogenous, or adoptively transferred expanded T reg cells in therapy.
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